The report highlights the trends prevalent in the global narcolepsy market and the factors driving the market along with those that act as deterrents to its growth.
Key factors driving the market are rising prevalence of sleep related disorders, emerging local pharmaceutical & biopharmaceutical companies, and increasing awareness regarding neurological disorders. However, factors such as side effects and risks associated with narcolepsy medications and delayed diagnosis or misdiagnosis of narcolepsy are likely to restrain the market growth to a certain extent.
Get PDF sample copy: https://www.theinsightpartners.com/sample/TIPRE00003326/
The narcolepsy market by type is segmented into narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary cataplexy. In 2018, the narcolepsy with cataplexy segment held a largest market share of 65.1% of the narcolepsy market, by type. This segment is also expected to dominate the market in 2027 owing to its significant prevalence among patients suffering with narcolepsy. Episodes of cataplexy are reported to be encountered among 55-60% of patients suffering with narcolepsy. Moreover, the similar segment is anticipated to also witness the fastest growth rate of 9.7% during the forecast period, 2019 to 2027 owing to the increasing demand for drugs to treat the disease.
Rising prevalence of sleep related neurological disorders is driving the market for narcolepsy over the forecast period.
The prominent players operating in narcolepsy market are Bioprojet, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., Graymark Healthcare, Inc., Arena Pharmaceuticals, Inc., Shire (Acquired by Takeda), Ligand Pharmaceuticals, Inc., Novartis AG, Mylan N.V., and Shionogi Inc.
The Asia Pacific narcolepsy market is expected to grow at highest rate during the forecast period owing higher number of research & development and increasing investments on sleep related neurological disorders. In addition, emergence of new local players with competitive drug portfolio are expected to fuel the market growth in Asia Pacific region.
Buy the complete report @ https://www.theinsightpartners.com/buy/TIPRE00003326/
Strategic Insights
Strategic acquisition and product launches were observed as the most adopted strategy in global narcolepsy industry. Few of the recent product launch and acquisitions are listed below:
2018: Jazz Pharmaceuticals announced FDA approval of Xyrem (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in pediatric narcolepsy patients
2019: Takeda Pharmaceutical Company Limited acquired Shire plc to expand its geographic footprint and leading position in Japan and the U.S.
2018: Jazz Pharmaceuticals announced FDA acceptance of supplemental new drug application for Xyrem (sodium oxybate) to treat cataplexy and excessive daytime sleepiness in pediatric narcolepsy patients
Media Contact
Company Name: The Insight Partners
Contact Person: Sam J
Email: Send Email
Phone: +1-646-491-9876
Address:Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/reports/narcolepsy-market